GlassScriptPhysician profile
Jonathan K Kushi
NPI 1073692901
$5,461.51
in general payments reported to CMS, 2019-2025
33 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $912 · 2021: $1,171 · 2022: $756 · 2023: $373 · 2024: $560 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216 · Education: $56.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.55 |
| Education | $56.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,172.55 | 2019-2025 | |
| Pfizer INC. | $689.08 | 2019-2024 | |
| Amgen INC. | $579.07 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $327.60 | 2021-2025 | Saphnelo |
| Ucb, INC. | $305.47 | 2019-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $300.02 | 2019-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $288.76 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $204.02 | 2019-2023 | Actemra |
| Sanofi-Aventis U.S. LLC | $168.08 | 2019-2020 | |
| Lilly USA, LLC | $151.12 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $135.86 | 2023-2025 | Strensiq, Ultomiris |
| Genzyme Corporation | $135.70 | 2019-2024 | |
| Horizon Therapeutics Plc | $121.46 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $116.41 | 2019-2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.19 | 2021-2025 | Cyltezo, Spevigo, Ofev |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $101.89 | 2023-2025 | Purified Cortrophin Gel |
| Ferring Pharmaceuticals INC. | $77.05 | 2019-2023 | Euflexxa |
| Mallinckrodt Hospital Products INC. | $69.10 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $63.04 | 2020-2025 | |
| Celltrion USA INC. | $56.36 | 2023-2024 | Yuflyma |
| Sobi, INC | $53.74 | 2020-2023 | |
| Aurinia Pharma U.S., INC. | $45.43 | 2021 | |
| Pacira Therapeutics, INC. | $28.24 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.65 | 2020 | |
| US Oncology Corporate, INC. | $19.42 | 2024 | |
| Janssen Scientific Affairs, LLC | $18.57 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $18.23 | 2024 | Arcalyst |
| Celgene Corporation | $16.93 | 2019 | |
| Hospira, INC. | $16.35 | 2025 | |
| Merck Sharp & Dohme LLC | $15.13 | 2021 | |
| Radius Health, INC. | $14.37 | 2019 | |
| Sandoz INC. | $13.47 | 2023 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $13.15 | 2023 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kushi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.